Publisher Correction: Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial

Affiliations

¹ Division of Endocrinology, University of California San Diego, La Jolla, CA, USA. jpettus@health.ucsd.edu.
² Division of Endocrinology, University of California San Diego, La Jolla, CA, USA.
³ Diablo Clinical Research, Walnut Creek, CA, USA.
⁴ Clinical Trials of Texas, San Antonio, TX, USA.
⁵ AMCR Institute, Escondido, CA, USA.
⁶ Barbara Davis Center for Diabetes, University of Colorado Anschutz Campus, Aurora, CO, USA.
⁷ Rainier Clinical Research Center, Renton, WA, USA.
⁸ Dallas Diabetes Research Center, Dallas, TX, USA.
⁹ Marin Endocrine Care and Research, Greenbrae, CA, USA.
¹⁰ Atlanta Diabetes Associates, Atlanta, GA, USA.
¹¹ REMD Biotherapeutics, Camarillo, CA, USA.
¹² Center for Human Nutrition, Washington University School of Medicine, St. Louis, MO and Sansum Diabetes Research Institute, Santa Barbara, CA, USA.

Published Erratum

Jeremy Pettus et al. Nat Med. 2023 Nov.

. 2023 Nov;29(11):2959.

doi: 10.1038/s41591-023-02301-y.

¹ Division of Endocrinology, University of California San Diego, La Jolla, CA, USA. jpettus@health.ucsd.edu.
² Division of Endocrinology, University of California San Diego, La Jolla, CA, USA.
³ Diablo Clinical Research, Walnut Creek, CA, USA.
⁴ Clinical Trials of Texas, San Antonio, TX, USA.
⁵ AMCR Institute, Escondido, CA, USA.
⁶ Barbara Davis Center for Diabetes, University of Colorado Anschutz Campus, Aurora, CO, USA.
⁷ Rainier Clinical Research Center, Renton, WA, USA.
⁸ Dallas Diabetes Research Center, Dallas, TX, USA.
⁹ Marin Endocrine Care and Research, Greenbrae, CA, USA.
¹⁰ Atlanta Diabetes Associates, Atlanta, GA, USA.
¹¹ REMD Biotherapeutics, Camarillo, CA, USA.
¹² Center for Human Nutrition, Washington University School of Medicine, St. Louis, MO and Sansum Diabetes Research Institute, Santa Barbara, CA, USA.

No abstract available

Erratum for

Glucagon receptor antagonist volagidemab in type 1 diabetes: a 12-week, randomized, double-blind, phase 2 trial.
Pettus J, Boeder SC, Christiansen MP, Denham DS, Bailey TS, Akturk HK, Klaff LJ, Rosenstock J, Cheng MHM, Bode BW, Bautista ED, Xu R, Yan H, Thai D, Garg SK, Klein S. Pettus J, et al. Nat Med. 2022 Oct;28(10):2092-2099. doi: 10.1038/s41591-022-02011-x. Epub 2022 Oct 3. Nat Med. 2022. PMID: 36192552 Free PMC article. Clinical Trial.